A. Wako's Unique Products - 3. Substrate for FDG-synthesis for PET diagnosis

a. Substrate for FDG-synthesis: Cancer Detection by PET* using a tracer, 18F-FDG  *: Positron emission tomography

1,3,4,6-Tetra-O-acetyl-2-O-trifluoromethanesulfonyl-β-D-mannopyranose
[Mannose Triflate], 98.0+% (HPLC)


Wako Catalog No. #209-16061 (5 x 20 mg); Keep at -20°C

Mannose Triflate is used as a substrate for synthesis of PET reagent, 18F-FDG. After nuclear transmutation of 18O to 18F in a cyclotron, 18F-FDG (2-deoxy-2-18F-fluoro-D-glucose) is automatically synthesized from Mannose Triflate. Once purified, it is used for PET examination.Since the half life of 18F is 2 hours, it is synthesized just before use in each hospital. FDG is characterized by a tendency to accumulate more in tumor cells than in normal cells. Therefore, it is effective in early detection of recurrence and metastasis of various types of cancer such as lung cancer, colon cancer and breast cancer.This product is packed in unit doses.


Example of imaging: It is observed that the tracer (18F-FDG) administered via the tail vein of rat is rapidly delivered to the heart, excreted via the liver ⇒ kidney ⇒ bladder, and accumulated in the cardiac muscle, retrobulbar area and brain.
[Features]]
1. 20 mg of Mannose Triflate in unit doses.
2. Rubber stopper and aluminum cap are used.
page top

B. Carcinogen

Model rodent colon carcinogen

Azoxymethane [AOM]


AOM induces colon cancer in mice and rats effectively, and is widely used as a substance to cause colon tumors in laboratory animals in the research of cancer prevention substances and the mechanism of cancer formation. In addition, amidst growing concerns over rising cases of colon cancer, the search for cancer prevention substances is believed to be increasingly popular, and thus the importance of the role this product plays is growing.The average dose of this product consists of a subcutaneous injection of 15 mg/kg (weight) in rats once a week, for a period of about 3 weeks. After a few weeks, precancerous lesions (ACF) are observed.


Description Wako Catalog No. (Pkg. Size) Induced Cancer, Storage condition
Azoxymethane [AOM],95.0+% (cGC)
<for Cellbiology>
011-20171 (100 mg) Colon cancer, Keep at -20°C
Related Products
7,12-Dimethylbenz[A]anthracene, 95.0+% (cGC) <Wako Special Grade> 042-02801 ( 1 g) Breast cancer, Keep at RT
DMIP [2-Amino-1,6-dimethylimidazo[4,5-b]pyridine], 98.0+% (HPLC) <for Biochemistry> 049-24891 ( 20 mg) Colon cancer, Keep at 2~10°C
4-Nitroquinoline 1-oxide, 98.0+% (HPLC) <Wako Special Grade> 147-03421 ( 1 g) Ovarian tumor, leukemia, Keep at 2~10°C
PhIP Hydrochloride, 99.0+% (HPLC) <for Biochemistry> 163-15951 (100 mg) Mouth cancer (tongue cancer), Keep at 2~10°C
page top
backindexnext
Wako Product Update Bio-No.3 [ page. 8 ]